Business
Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress
— Poster Presentations Highlight Company's Broad Research Commitment to Serious Mental Illness, Addiction and Narcolepsy — DUBLIN, Sept. 11, 2023 /PRNewswire/
About this update from Alkermes Plc
[{"type":"text","content":"— Poster Presentations Highlight Company's Broad Research Commitment to Serious Mental Illness, Addiction and Narcolepsy —\nDUBLIN, Sept. 11, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville. This research reflects the company's continued commitment to improving care for, and understanding the unique needs of, people living with serious chronic diseases.\n\"Psych Congress offers an important opportunity for scientific exchange and information sharing as we seek to advance care for people living with serious, complex diseases. This year's presentations further reinforce Alkermes' leadership and experience in the field of neuroscience,\" said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes.\nHighlights of the presentations include:\nThe first real-world data assessment of healthcare resource use in patients with schizophrenia or bipolar I disorder in the six months following initiation of LYBALVI® (olanzapine and samidorphan);Findings from a meta-analysis using individual subject-level data across three randomized, double-blind, controlled clinical trials designed to assess changes in body weight as either a primary or secondary endpoint in patients who received LYBALVI compared to those who received olanzapine;Three posters describing the first set of results from OASIS (Observational Study of Long-Acting Injectables in Schizophrenia), a prospective, noninterventional study evaluating the use of second-generation long-acting injectables (LAIs) in community clinics, including during the COVID-19 pandemic;Post-hoc analyses of the ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness) study, in which patients with schizophrenia were randomized to receive either the two-month dose of ARISTADA® (aripiprazole lauroxil) initiated in an inpatient setting using ARISTADA INITIO® (aripiprazole lauroxil) plus a single 30 mg oral dose of olanzapine, or an active control of paliperidone palmitate; andResults from a recently completed, structured qualitative interview study evaluating the diagnosis journey and symptoms of adults living with narcolepsy type 1 and ...